Abstract
This review focuses on the role of T lymphocytes in the pathogenesis of Parkinson's disease and highlights evidence for modulation of the T cell response as an effective neuroprotective strategy. In preclinical models of Parkinson's disease, modulation of the T cell response results in neuroprotection. Peripheral markers of T cell response show changes in Parkinson's patients relative to controls that have potential application as diagnostic and therapeutic biomarkers. The article also discusses the important immunomodulatory effects of dopamine which may confound study of T cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, as a promising target for translation.
| Original language | English (US) |
|---|---|
| Journal | Parkinsonism and Related Disorders |
| DOIs | |
| State | Accepted/In press - Jan 1 2018 |
Fingerprint
Keywords
- Biomarkers
- Dopamine
- Glatiramer acetate
- Immunomodulation
- Neuroinflammation
- Neuroprotection
- Parkinson's disease
- Pathogenesis
- T cells
- T lymphocytes
ASJC Scopus subject areas
- Neurology
- Geriatrics and Gerontology
- Clinical Neurology
Cite this
The key role of T cells in Parkinson's disease pathogenesis and therapy. / Baird, Jill K.; Bourdette, Dennis; Meshul, Charles K.; Quinn, Joseph.
In: Parkinsonism and Related Disorders, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The key role of T cells in Parkinson's disease pathogenesis and therapy
AU - Baird, Jill K.
AU - Bourdette, Dennis
AU - Meshul, Charles K.
AU - Quinn, Joseph
PY - 2018/1/1
Y1 - 2018/1/1
N2 - This review focuses on the role of T lymphocytes in the pathogenesis of Parkinson's disease and highlights evidence for modulation of the T cell response as an effective neuroprotective strategy. In preclinical models of Parkinson's disease, modulation of the T cell response results in neuroprotection. Peripheral markers of T cell response show changes in Parkinson's patients relative to controls that have potential application as diagnostic and therapeutic biomarkers. The article also discusses the important immunomodulatory effects of dopamine which may confound study of T cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, as a promising target for translation.
AB - This review focuses on the role of T lymphocytes in the pathogenesis of Parkinson's disease and highlights evidence for modulation of the T cell response as an effective neuroprotective strategy. In preclinical models of Parkinson's disease, modulation of the T cell response results in neuroprotection. Peripheral markers of T cell response show changes in Parkinson's patients relative to controls that have potential application as diagnostic and therapeutic biomarkers. The article also discusses the important immunomodulatory effects of dopamine which may confound study of T cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, as a promising target for translation.
KW - Biomarkers
KW - Dopamine
KW - Glatiramer acetate
KW - Immunomodulation
KW - Neuroinflammation
KW - Neuroprotection
KW - Parkinson's disease
KW - Pathogenesis
KW - T cells
KW - T lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85055953816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055953816&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2018.10.029
DO - 10.1016/j.parkreldis.2018.10.029
M3 - Article
C2 - 30404763
AN - SCOPUS:85055953816
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
SN - 1353-8020
ER -